Free shipping on all orders over $ 500

EDP-305

Cat. No. M22512

All AbMole products are for research use only, cannot be used for human consumption.

EDP-305 Structure
Synonym:

EDP305

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

Quality Control & Documentation
Biological Activity

EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 can be used for the research of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). EDP-305 (0-5 μM, 16 h) increases the expression of the FXR target gene, SHP, and downregulates CYP7A1 expression in HepaRG hepatocytes. 

EDP‐305 (0-30 mg/kg, Oral gavage, daily for 2 weeks) reduces serum markers of liver injury, and reduces liver fibrosis in a dose-dependent manner in BDL rats. EDP‐305 (0-30 mg/kg, Oral gavage, daily for 6 weeks) reduces liver fibrosis in a dose-dependent manner in CDAHFD mice.

Chemical Information
Molecular Weight 630.92
Formula C36H58N2O5S
CAS Number 1933507-63-1
Solubility (25°C) DMSO 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Alaa Ahmad, et al. Clin Transl Sci. Assessment of drug-drug interaction potential with EDP-305, a farnesoid X receptor agonist, in healthy subjects

[2] Vlad Ratziu, et al. J Hepatol. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study

[3] Claus Kremoser. J Hepatol. FXR agonists for NASH: How are they different and what difference do they make?

[4] Ping An, et al. Liver Int. A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

[5] Shen Li, et al. FASEB J. The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction

Related Farnesoid X Receptor Products
ZLY28

ZLY28 is a first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 is also a novel anti-NASH agent.
ASC-42

ASC-42 is a novel, potentially best-in-class, highly potent and selective non-steroidal FXR agonist that also inhibits the transcription of HBV RNA to hepatitis B surface antigen by inhibiting the transcription of HBV covalent closed-circle DNA (cccDNA) to HBV RNA.
Linafexor

Linafexor is a bile acid receptor (FXR) agonist that may be used in studies related to cholangitis and non-alcoholic steatohepatitis.
MET-409

MET-409 is an oral non-steroidal bile acid receptor FXR agonist for studies related to inflammatory bowel disease and irritable bowel syndrome.
FXR agonist 5

FXR agonist 5 is a FXR agonist.
  Catalog
Abmole Inhibitor Catalog




Keywords: EDP-305, EDP305 supplier, Farnesoid X Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.


 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.